Avadel Pharmaceuticals PLC (AVDL)vsTeva Pharma Industries Ltd ADR (TEVA)
AVDL
Avadel Pharmaceuticals PLC
$21.64
0.00%
HEALTHCARE · Cap: $2.12B
TEVA
Teva Pharma Industries Ltd ADR
$40.06
-1.35%
HEALTHCARE · Cap: $45.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 6867% more annual revenue ($17.32B vs $248.52M). TEVA leads profitability with a 4.1% profit margin vs -0.0%. AVDL appears more attractively valued with a PEG of 0.07. TEVA earns a higher WallStSmart Score of 46/100 (D+).
AVDL
Hold41
out of 100
Grade: D
TEVA
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.2%
Fair Value
$70.24
Current Price
$21.64
$48.60 discount
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
0.5% revenue growth
0.0% earnings growth
Operating margin of 0.0%
Weak financial health signals
4.1% margin — thin
Operating margin of 4.0%
Premium valuation, high expectations priced in
Revenue declined 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : AVDL
The strongest argument for AVDL centers on PEG Ratio. PEG of 0.07 suggests the stock is reasonably priced for its growth.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.71 suggests the stock is reasonably priced for its growth.
Bear Case : AVDL
The primary concerns for AVDL are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : TEVA
The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 65.0x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
AVDL profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.
AVDL carries more volatility with a beta of 1.63 — expect wider price swings.
AVDL is growing revenue faster at 0.5% — sustainability is the question.
TEVA generates stronger free cash flow (307M), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (46/100 vs 41/100). AVDL offers better value entry with a 69.2% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Avadel Pharmaceuticals PLC
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Avadel Pharmaceuticals plc is a biopharmaceutical company in the United States. The company is headquartered in Dublin, Ireland.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?